



Supplementary Figure 1. Differences in decline of the TGF β -15 specific immune responses in patients with lasting clinical benefit vs. patients without lasting clinical benefit.

Comparison of TGF β -15 specific immune response at baseline and after four series of treatment in patients with lasting clinical benefit (left) and without lasting clinical benefit (right).

Lasting clinical benefit defined as a PR or SD lasting longer than 6 months. Statistics made using Wilcoxon matched-pairs signed rank test.